Tumor-associated antigen (MM200 melanoma cell line) (TAA-MM200)

Tumor-associated antigens from MM200 melanoma cells are a complex mixture of immunogenic molecules, primarily proteins and glycoproteins, expressed by the MM200 human melanoma cell line. These antigens were historically utilized as a key component of Canvaxin, a polyvalent whole-cell vaccine designed to treat metastatic melanoma (Morton et al., 2002). The vaccine aimed to stimulate a systemic immune response by exposing the patient's immune system to a broad array of melanoma-specific epitopes, thereby encouraging the destruction of endogenous tumor cells. One of the most well-characterized antigens within this group is TA90, a 90-kDa glycoprotein that serves as a biomarker for disease progression and vaccine efficacy (Hsueh et al., 1998). Despite showing significant promise in Phase II trials, the development of therapies targeting these antigens was halted after a Phase III trial failed to demonstrate a survival benefit over placebo (Faries et al., 2017). Today, these antigens are primarily of historical and research interest in the field of cancer vaccinology and immune monitoring.

Other names

MM200 antigensMelanoma-associated antigensCanvaxin componentsMelanoma cell vaccine antigens

Stimulation of active specific immunotherapy through the induction of polyvalent humoral and cellular immune responses against melanoma-associated antigens.